Program
GLK-321
A development code. Also written as “GLK-321 low dose BID”, “GLK-321 mid dose BID” and “GLK-321 high dose BID”.
Its studies are mostly in Blepharitis, led by Glaukos.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Glaukos | 11 open or running | phase 2since Feb 3, 2026 | Feb 3, 2026 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 3, 2026First study: phase 2 study in Demodex BlepharitisFirst studyNCT07400965 · 250 planned · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07400965Demodex Blepharitis · United States | 2 | Recruiting | Sep 2026 | 250 |
How it is read
Names in the registry
- “GLK-321 low dose BID”, 1 entry
- “GLK-321 mid dose BID”, 1 entry
- “GLK-321 high dose BID”, 1 entry
- “GLK-321 high dose QD”, 1 entry
Codes read as this program: GLK321.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.